How is desmopressin vasopressin analog administered for the treatment of hemophilia A?

Updated: Jun 05, 2020
  • Author: Douglass A Drelich, MD; Chief Editor: Srikanth Nagalla, MBBS, MS, FACP  more...
  • Print

DDAVP may result in sufficient hemostasis to stop a bleeding episode or to prepare patients for dental and minor surgical procedures. A test dose should be performed before prophylactic use. It can be intravenously administered at a dose of 0.3 mcg/kg of body weight in the inpatient setting. Its peak effect is observed in 30-60 minutes.

If the test dose produces an appropriate rise in the FVIII level, at least 1 week should elapse before performance of any procedures. This allows time for replenishment of endogenous stores of FVIII, so that an adequate DDAVP-induced rise in FVIII is obtained for the procedure.

A concentrated DDAVP intranasal spray (1.5 mg/mL) is available for outpatient use. Its effectiveness is similar to that of the intravenous preparation, although its peak effect is observed later, at 60-90 minutes after administration.

Did this answer your question?
Additional feedback? (Optional)
Thank you for your feedback!